1
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (19 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2

3
Coleman Paul J, Fraley Mark E, Hoffman William F: Mitotic kinesin inhibitors. Merck & Co, Coleman Paul J, Fraley Mark E, Hoffman William F, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, May 13, 2004: WO/2004/039774 (72 worldwide citation)

The present invention relates to azaquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and method ...


4
Buser Doepner Carolyn A, Coleman Paul J, Cox Christopher D, Fraley Mark E, Garbaccio Robert M, Hartman George D, Heimbrook David C, Kuo Lawrence C, Huber Hans E, Sardana Vinod V, Torrent Maricel, Yan Youwei: Mitotic kinesin binding site. Merck & Co, Buser Doepner Carolyn A, Coleman Paul J, Cox Christopher D, Fraley Mark E, Garbaccio Robert M, Hartman George D, Heimbrook David C, Kuo Lawrence C, Huber Hans E, Sardana Vinod V, Torrent Maricel, Yan Youwei, KOHLI Vineet, January 15, 2004: WO/2004/004652 (41 worldwide citation)

The present invention is directed to the identification, characterization and three-dimensional structure of a novel ligand binding site of KSP. Binding of ligands to the novel binding site result in a conformational change in the three-dimensional structure of the protein and a modulation of the ac ...


5
Fraley Mark E: Tyrosine kinase inhibitors. Merck & Co, Fraley Mark E, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 24, 2004: WO/2004/052315 (26 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


6
Fraley Mark E, Hambaugh Scott R, Rubino Robert S, Hungate Randall W: Tyrosine kinase inhibitors. Merck & Co, Fraley Mark E, Hambaugh Scott R, Rubino Robert S, Hungate Randall W, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 24, 2004: WO/2004/052286 (18 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


7
Brnardic Edward J, Converso Antonella, Fraley Mark E, Garbaccio Robert M, Huang Shaei Y: Oxazolobenzimidazole derivatives. Merck & Co, Brnardic Edward J, Converso Antonella, Fraley Mark E, Garbaccio Robert M, Huang Shaei Y, Merck & Co, November 19, 2009: WO/2009/140163 (17 worldwide citation)

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


8
Brnardic Edward J, Fraley Mark E, Garbaccio Robert M: Oxazolobenzimidazole derivatives. Merck & Co, Brnardic Edward J, Fraley Mark E, Garbaccio Robert M, Merck & Co, November 19, 2009: WO/2009/140166 (17 worldwide citation)

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...


9
Arrington Kenneth L, Fraley Mark E, Hartman George D: Mitotic kinesin inhibitors. Merck & Co, Arrington Kenneth L, Fraley Mark E, Hartman George D, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 21, 2005: WO/2005/065183 (13 worldwide citation)

The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and ...


10
Cox Christopher D, Fraley Mark E, Garbaccio Robert M: Mitotic kinesin inhibitors. Merck & Co, Cox Christopher D, Fraley Mark E, Garbaccio Robert M, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, March 23, 2006: WO/2006/031348 (9 worldwide citation)

The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them ...



Click the thumbnails below to visualize the patent trend.